Riik: Kanada
keel: inglise
Allikas: Health Canada
ROCURONIUM BROMIDE
OMEGA LABORATORIES LIMITED
M03AC09
ROCURONIUM BROMIDE
10MG
SOLUTION
ROCURONIUM BROMIDE 10MG
INTRAVENOUS
10X5ML/10X10ML
Prescription
NEUROMUSCULAR BLOCKING AGENTS
Active ingredient group (AIG) number: 0126317001; AHFS:
APPROVED
2012-03-23
_Rocuronium Bromide Injection Product Monograph _ _Page 1 of 35 _ PRODUCT MONOGRAPH Pr ROCURONIUM BROMIDE INJECTION Rocuronium Bromide 10 mg/mL Solution for Injection Non-depolarizing Skeletal Neuromuscular Blocking Agent Omega Laboratories Ltd. 11 177 Hamon Montréal, Québec, H3M 3E4 Date of Preparation: March 23, 2012 Submission Control No. 140885 _Rocuronium Bromide Injection Product Monograph _ _Page 2 of 35 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...........................................3 SUMMARY PRODUCT INFORMATION .................................................................3 INDICATIONS AND CLINICAL USE ........................................................................3 CONTRAINDICATIONS .............................................................................................3 WARNINGS AND PRECAUTIONS ............................................................................4 ADVERSE REACTIONS ..............................................................................................8 DRUG INTERACTIONS ..........................................................................................11 DOSAGE AND ADMINISTRATION ........................................................................12 OVERDOSAGE .........................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY .....................................................18 STORAGE AND STABILITY ....................................................................................26 SPECIAL HANDLING INSTRUCTIONS ................................................................26 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................... 26 PART II: SCIENTIFIC INFORMATION ................................................................28 PHARMACEUTICAL INFORMATION ....................................................................28 CLINICAL TRIALS .............................................................................. Lugege kogu dokumenti